Nicotinamide N-methyltransferase (
NNMT), a major metabolic regulator, has been identified as a predictor of
cancer prognosis in ovarian and
colorectal cancers. The study aims to evaluate the significance of stromal
NNMT in
gastric cancer (GC). Expression of stromal
NNMT in 612 GC and 92 non-malignant tissues specimens was investigated by immunohistochemistry (IHC). The association between
NNMT expression and occurrence of
cancer or patient outcome was further analyzed, and the factors contributing to disease prognosis were evaluated by multiple Cox models. Stromal
NNMT expression was higher in the malignant tissue (p<0.001).
NNMT expression was significantly associated with GC stage (p=0.006). Compared to stromal "
NNMT-low" cases, "
NNMT-high" cases has lower disease-specific survival (hazard ratio [HR], 2.356; 95% confidence interval [CI] = 1.591-3.488; p<0.001) and disease-free survival (HR = 2.265; 95% CI = 1.529-3.354; p<0.001), as observed by multivariate Cox analysis after adjusting for stromal
NNMT expression with other factors such as
tumor grade and size. Notably, patients with stage II
NNMT-low GC might be negatively affected by
adjuvant chemotherapy, but lower stromal
NNMT expression predicted a more favorable prognosis for GC. Our study confirmed that stromal
NNMT expression is significantly increased in GC, which predicts an unfavorable post-operative prognosis for GC.